We know that we won’t discover everything inside our own labs and that we need to partner with other companies, academic institutions and research charities. This is especially true in areas where research is particularly difficult, for example in the science around antibiotics, and where illnesses are proving particularly hard to understand, like Alzheimer’s disease.
We currently have research collaborations with thousands of external organisations, including other companies, academic institutions and research charities. And we’re adding to this number every year. We’re also partnering with governments, charities and other organisations on innovative funding mechanisms, enabling us to share the costs of research into diseases and illnesses that are proving particularly difficult to solve.
And in the case of illnesses that have a disproportionate impact on developing countries – like malaria or tuberculosis – we have a different challenge: these countries have a pressing need for new treatments, yet they are the very countries that can least afford to pay for them.
In these regions, we need to come up with radically different ways of supporting our R&D. To do this, we’re stimulating innovation in new ways, looking outside our own labs and opening up access to our expertise, our facilities and even our intellectual property.
Partnerships with academic institutions
We have established over 500 research partnerships with universities and academic institutions globally. We also provide support for science students through fellowships and other awards. This helps advance scientific understanding and capability, and gives us access to R&D expertise outside of GSK. It also expands our potential recruitment pool of trained scientists, while our academic partners benefit from having access to our research facilities, technology and expertise.
More open innovation
Diseases of the developing world
To achieve sustainable improvements in access to essential care and medicines in the developing world, we need to have a dedicated strategy devoted to it
Non-communicable diseases in Africa
A collaborative approach to helping us to better understand non-communicable diseases (NCDs) in Africa
Stevenage bioscience hub
The Stevenage Bioscience Catalyst campus is a major hub for early-stage biotechnology companies
Targeting the immune system through open innovation
We have at least 10 research units focused on immunology across several therapeutic areas and have multiple research programmes underway